Stock Performance - The stock of Xin Gan Jiang recently experienced significant activity, with a closing price of 30.55 yuan per share on January 13, 2026, and a trading volume of 2.45 billion yuan, indicating high short-term trading sentiment [2] - The dynamic price-to-earnings ratio stands at 195.47, suggesting potential volatility in the stock price moving forward [2] Funding Situation - As of December 31, 2025, Xin Gan Jiang's financing balance was 12.53 million yuan, accounting for 0.88% of its market capitalization, which is above the 50th percentile over the past year, indicating a high level of financing [3] Operational Performance - According to the Q3 2025 report, Xin Gan Jiang's revenue for the first three quarters was 97.24 million yuan, a year-on-year decrease of 12.69%, while net profit attributable to shareholders was 8.31 million yuan, down 59.02% year-on-year [4] - The decline in net profit is attributed to reduced government subsidies and decreased revenue, although the gross profit margin increased by 2.55 percentage points to 43.98%, and R&D expenses rose by 71.33% [4] Fund Management Strategy - In September 2025, Xin Gan Jiang announced the purchase of wealth management products from Shangrao Bank totaling 20 million yuan, with an outstanding balance of 163 million yuan in wealth management products as of September 24, 2025, representing 34.30% of net assets [5]

Core Viewpoint - The stock of Xin Gan Jiang has experienced an abnormal fluctuation, with a cumulative increase of 42.73% in closing prices over the last three trading days from January 9 to January 13, 2026 [2] Company Summary - Xin Gan Jiang announced that the recent stock price increase falls under the category of abnormal trading fluctuations [2] - The company conducted an internal review and found no need to amend or supplement previous announcements [2] - There were no significant media reports or market rumors that could have influenced the stock price [2] - The operational situation and external environment of the company have not undergone any major changes [2] - The company, its controlling shareholders, and actual controllers do not have any undisclosed significant matters [2]

Core Viewpoint - New Ganjiang (920367) experienced a trading halt today, reaching a daily limit increase of 30.00%, with a turnover rate of 21.46% and a total transaction amount of 271 million yuan [2] Trading Activity - The stock was listed on the North Exchange due to its daily price fluctuation limit being reached, with a net buying amount of 9.4733 million yuan from brokerage seats [2] - According to statistics from Securities Times·Data Treasure, the top five brokerage seats accounted for a total transaction amount of 80.2792 million yuan, with a buying transaction amount of 44.8763 million yuan and a selling transaction amount of 35.4029 million yuan, resulting in a net buying of 9.4733 million yuan [2] Brokerage Seat Details - The largest buying brokerage seat was Guotai Junan Securities Co., Ltd. Shanghai Jiangsu Road Brokerage Seat, with a buying amount of 13.2618 million yuan, while the largest selling brokerage seat was Tianfu Securities Co., Ltd. Shanghai Laoshan Road Brokerage Seat, with a selling amount of 9.4705 million yuan [2] - Detailed trading information for January 13 shows the top five buying and selling brokerage seats, with significant buying from Guotai Junan and selling from Tianfu Securities [2]

Core Viewpoint - On January 13, 2026, the company Xinganjiang (920367) experienced a significant stock price increase of 30.00%, leading to its appearance on the trading leaderboard with a trading volume of 8.9648 million shares and a transaction value of 271 million yuan [1][2]. Group 1: Trading Activity - The closing price of Xinganjiang reached 30.55 yuan, marking a 30.00% increase on the trading day [1]. - The total trading volume for the day was 8.9648 million shares, with a total transaction value of 271 million yuan [1]. - The top buying seat was from Guotai Junan Securities Co., Ltd., Shanghai Jiangsu Road Branch, which purchased shares worth 13.26 million yuan [2]. - The top selling seat was from Tianfu Securities Co., Ltd., Shanghai Laoshan Road Branch, which sold shares worth 9.47 million yuan [2]. Group 2: Detailed Trading Data - The second highest buying seat was from Founder Securities Co., Ltd., Changsha Huangxing Middle Road Branch, with a purchase amount of 11.42 million yuan [2]. - Other notable buying seats included Shanghai Securities Co., Ltd., Ningbo Beilun Xinda Road Branch (7.41 million yuan) and Dongya Qianhai Securities Co., Ltd., Shenzhen Branch (6.83 million yuan) [2]. - On the selling side, the second highest was Huazhang Securities Co., Ltd., Xinxiang Jinsui Avenue Branch, with a selling amount of 8.11 million yuan [2].

Group 1 - The chemical pharmaceutical sector increased by 0.56% on January 13, with Xin Ganjiang leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] - Notable stock performances included Xin Ganjiang with a closing price of 30.55, up 30.00%, and Erkang Pharmaceutical at 4.45, up 19.95% [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 929 million yuan from institutional investors, while retail investors experienced a net outflow of 903 million yuan [2] - Major stocks with significant net inflows included Erkang Pharmaceutical with 240 million yuan and Xin Ganjiang with 189 million yuan [3] - Retail investors showed a negative trend, with significant outflows from stocks like Yipin Hong and Chuaning Biological [3]

Core Insights - New Ganjing (920367) reported a net financing purchase of 191.3 million yuan on November 14, with a total financing balance of 1,548.9 million yuan, marking a continuous net purchase of 381.81 million yuan over the last three trading days [1][2]. Financing Activity Summary - On November 14, the net financing purchase was 191.3 million yuan, with a financing balance of 1,548.9 million yuan, representing 1.53% of the circulating market value [2]. - The financing balance increased by 14.09% compared to the previous day, reflecting a significant rise in investor activity [3]. - Over the past three trading days, the net financing purchases were as follows: 79.74 million yuan on November 13, 110.76 million yuan on November 12, and 40.97 million yuan on November 11 [2][3].

Core Insights - New Ganjing (920367.BJ) released its Q3 2025 report on October 30, 2025, indicating a total of 5 institutional investors holding shares, amounting to 6.3421 million shares, which represents 8.95% of the total share capital [1] Institutional Holdings - The institutional investors include: - Ji'an Jizhou District Kaida Enterprise Management Consulting Center (Limited Partnership) - Huatai Securities Co., Ltd. Client Credit Trading Guarantee Securities Account (two accounts) - Huasan Securities Co., Ltd. Client Credit Trading Guarantee Securities Account (two accounts) - The total institutional holding ratio increased by 0.83 percentage points compared to the previous quarter [1] Public Fund Holdings - One public fund, Tongtai Vision Mixed A, was disclosed this period, which was not reported in the previous quarter [1]

公司本次以部分闲置自有资金购买理财产品的金额合计 2,000 万元。截止 本公告日，公司闲置自有资金购买理财产品的未到期产品余额为人民币 16,255 万元，占公司 2024 年年度经审计净资产（归属于母公司的）的 34.30%。 二、 本次委托理财情况 证券代码：873167 证券简称：新赣江 公告编号：2025-109 江西新赣江药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）审议情况 公司于 2025 年 4 月 1 日召开了第三届董事会第八次会议、2025 年 4 月 22 日召开了 2025 年第一次临时股东会，审议通过了《关于使用闲置自有资金购 买理财产品的议案》，公司拟继续使用闲置自有资金购买理财产品，额度不变， 仍为单笔购买理财产品金额或任一时点持有未到期的理财产品余额不超过人 民币 1.65 亿元（含 1.65 亿元），期限为股东会审议通过之日起一年，在上述 额度和期限内，资金可以滚动使用。具体 ...

财通证券股份有限公司 关于江西新赣江药业股份有限公司 2025年上半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则》 （以下简称《上市规则》）等有关法律法规、规范性文件等的规定，财通证券股 份有限公司（以下简称"财通证券""保荐机构"）作为江西新赣江药业股份有 限公司（以下简称"新赣江""公司"）的保荐机构，负责新赣江的持续督导工 作，并出具2025年上半年度持续督导跟踪报告。 一、持续督导工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情 | 保荐机构及时审阅了公司信息披露文件。 | | 况 | | | 2、督导公司建立健全并 | 保荐机构督导公司建立健全规则制度（包括但不限于根据新《公 | | 有效执行规则制度的情 | 司法》及《上市规则》的规定，修改完善公司治理制度，本督导 | | 况 | 期内，新赣江有效执行了规则制度。 | | 3、募集资金使用监督情 | 保荐机构定期查阅公司募集资金账户对账单，核查公司募集资金 使用情况；前往公司现场核查募集资金使用情况。本督导期内， | | 况 | | | | 新赣江募集资金存放与使 ...

证券代码：873167 证券简称：新赣江 公告编号：2025-107 江西新赣江药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）审议情况 公司于 2025 年 4 月 1 日召开了第三届董事会第八次会议、第三届监事会 第八次会议、2025 年 4 月 22 日召开了 2025 年第一次临时股东会，审议通过 了《关于使用闲置自有资金购买理财产品的议案》，公司拟继续使用闲置自有 资金购买理财产品，额度不变，仍为单笔购买理财产品金额或任一时点持有未 到期的理财产品余额不超过人民币 1.65 亿元（含 1.65 亿元），期限为股东会 审议通过之日起一年，在上述额度和期限内，资金可以滚动使用。具体内容详 见公司在北京证券交易所信息披露平台（www.bse.cn）披露的《关于使用闲置 自有资金购买理财产品的公告》（公告编号：2025-013）。 （二）披露标准 根据《北京证券交易所股票上市规则》的相关规定，交易的成交金额占上 ...